Arthur Kuan

Arthur Kuan is the Chief Executive Officer and Chairman of CG Oncology, a clinical-stage biotechnology company focused on developing innovative oncolytic immunotherapy treatments for urologic cancers, particularly bladder cancer. He has been with the company since 2014, initially joining as an early investor before taking on a full-time role. Under his leadership, CG Oncology aims to provide bladder-saving therapeutics that enhance the quality of life for patients suffering from these conditions.123

Background and Education

Arthur Kuan holds a Master of Science (M.S.) in Biotechnology from The Johns Hopkins University and a Bachelor of Arts (B.A.) in Molecular Biology from the University of Pennsylvania. His academic background equips him with a strong foundation in the life sciences, which is integral to his work in biotechnology.12

Career Highlights

• CEO at CG Oncology: Since September 2016, he has led the company, emphasizing innovative therapies for urologic cancer.
• Recognition: Kuan was named a Forbes 30 Under 30 honoree in Healthcare in 2020, highlighting his influence and contributions to the field at a young age.23
• Board Memberships: He serves on the IP Commercialization Strategy Committee at the Moffitt Cancer Center, where he advises on intellectual property matters related to innovation in cancer treatment.13

Personal Motivation

Kuan's commitment to oncology is deeply personal; he lost his father to cancer, which fuels his passion for developing effective cancer therapies. His leadership at CG Oncology reflects not only professional ambition but also a personal mission to improve patient outcomes in urologic oncology.3

Additional Involvement

Before his current role, Kuan was involved with various investment groups focusing on healthcare innovations, including serving as a founding member of Ally Bridge Group and working with Themes Investment Management.23